Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy

The overall assessment of the study also showed trends that patients undergoing more invasive interventions and procedures requiring higher volumes of contrast medium experienced a stronger benefit from the RUCONEST® treatment. “Reaching a significant difference already in a small number of patients in this well-run exploratory trial gives a surprisingly clear positive signal in what could become a large new indication for RUCONEST®.” — Bruno Giannetti - COO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗